22 related articles for article (PubMed ID: 12804847)
1. Evidence that Par-4 participates in the pathogenesis of HIV encephalitis.
Kruman II; Nath A; Maragos WF; Chan SL; Jones M; Rangnekar VM; Jakel RJ; Mattson MP
Am J Pathol; 1999 Jul; 155(1):39-46. PubMed ID: 10393834
[TBL] [Abstract][Full Text] [Related]
2. What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?
Campbell GR; Loret EP
Retrovirology; 2009 May; 6():50. PubMed ID: 19467159
[TBL] [Abstract][Full Text] [Related]
3. Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
Watkins JD; Lancelot S; Campbell GR; Esquieu D; de Mareuil J; Opi S; Annappa S; Salles JP; Loret EP
Retrovirology; 2006 Jan; 3():8. PubMed ID: 16441880
[TBL] [Abstract][Full Text] [Related]
4. Sequence variation within the dominant amino terminus epitope affects antibody binding and neutralization of human immunodeficiency virus type 1 Tat protein.
Ruckwardt TJ; Tikhonov I; Berg S; Hatfield GS; Chandra A; Chandra P; Gilliam B; Redfield RR; Gallo RC; Pauza CD
J Virol; 2004 Dec; 78(23):13190-6. PubMed ID: 15542671
[TBL] [Abstract][Full Text] [Related]
5. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen.
Moreau E; Hoebeke J; Zagury D; Muller S; Desgranges C
J Virol; 2004 Apr; 78(7):3792-6. PubMed ID: 15016898
[TBL] [Abstract][Full Text] [Related]
6. Antigenic variation of primate lentiviruses in humans and experimentally infected macaques.
Fenyö EM
Immunol Rev; 1994 Aug; 140():131-46. PubMed ID: 7821925
[TBL] [Abstract][Full Text] [Related]
7. Minimization of chronic plasma viremia in rhesus macaques immunized with synthetic HIV-1 Tat peptides and infected with a chimeric simian/human immunodeficiency virus (SHIV33).
Goldstein G; Manson K; Tribbick G; Smith R
Vaccine; 2000 Jun; 18(25):2789-95. PubMed ID: 10812220
[TBL] [Abstract][Full Text] [Related]
8. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein.
Silvera P; Richardson MW; Greenhouse J; Yalley-Ogunro J; Shaw N; Mirchandani J; Khalili K; Zagury JF; Lewis MG; Rappaport J
J Virol; 2002 Apr; 76(8):3800-9. PubMed ID: 11907220
[TBL] [Abstract][Full Text] [Related]
9. A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.
Demberg T; Florese RH; Heath MJ; Larsen K; Kalisz I; Kalyanaraman VS; Lee EM; Pal R; Venzon D; Grant R; Patterson LJ; Korioth-Schmitz B; Buzby A; Dombagoda D; Montefiori DC; Letvin NL; Cafaro A; Ensoli B; Robert-Guroff M
J Virol; 2007 Apr; 81(7):3414-27. PubMed ID: 17229693
[TBL] [Abstract][Full Text] [Related]
10. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
[TBL] [Abstract][Full Text] [Related]
11. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
12. Specificity and effect on apoptosis of Tat antibodies from vaccinated and SHIV-infected rhesus macaques and HIV-infected individuals.
Belliard G; Romieu A; Zagury JF; Dali H; Chaloin O; Le Grand R; Loret E; Briand JP; Roques B; Desgranges C; Muller S
Vaccine; 2003 Jul; 21(23):3186-99. PubMed ID: 12804847
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
